Generate Biomedicines, Inc.
GENB
Rank in Stocks
#6251
Generate Biomedicines, Inc. is a U.S.-based company pioneering generative... Generate Biomedicines, Inc. is a U.S.-based company pioneering generative biology, leveraging machine learning for the discovery and advancement of novel protein therapeutics. Their core approach involves developing drugs using protein-based modalities. The company's pipeline includes several key candidates: GB-0895, an investigational long-acting anti-TSLP monoclonal antibody designed for bi-annual dosing in severe asthma; GB-4362, an MMAE payload neutralizer monoclonal antibody; and GB-5267, a MUC16 CAR-T cell therapy. Integral to their work is the Generate Platform, a sophisticated system engineered to be versatile across diverse therapeutic areas and protein modalities. This platform combines computational innovation with scalable biohardware, allowing them to tackle therapeutic hurdles beyond the capabilities of traditional technologies. Established in 2018, the company was initially known as Generate Biologics, Inc. before rebranding to Generate Biomedicines, Inc. in February 2020. Its headquarters are located in Somerville, Massachusetts.
Share Price
$14.18
Last synced: 2026-11-09
Market Cap
$1.82B
Change (1 day)
8.58%
Change (1 year)
-
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Generate Biomedicines, Inc. (GENB)
Category
Healthcare
Operating Margin for Generate Biomedicines, Inc. (GENB)
Operating Margin as of November 2026 TTM: -827.60%
According to Generate Biomedicines, Inc.'s latest financial reports, its current operating margin (TTM) is -827.60%. At the end of 2025 the company had an operating margin of -737.04%.
Operating Margin history for Generate Biomedicines, Inc. from 2024 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -827.60% | 12.29% |
| 2025 | -737.04% | -23.43% |
| 2024 | -962.60% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -100.05% |
US
|
|
| -149.01% | -99.82% |
US
|
|
| 25.57% | -100.03% |
AU
|
|
| 31.23% | -100.04% |
BE
|
|
| 29.35% | -100.04% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Generate Biomedicines, Inc.'s operating margin
What is Generate Biomedicines, Inc.'s operating margin?
Generate Biomedicines, Inc.'s operating margin is -827.60%, as of Nov 2026.
What was Generate Biomedicines, Inc.'s operating margin in 2025?
In 2025, Generate Biomedicines, Inc.'s operating margin was -737.04%, compared with -962.60% in 2024.
How does Generate Biomedicines, Inc.'s operating margin compare with similar companies?
Generate Biomedicines, Inc.'s operating margin (-827.60%) is lower than that of all 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.